NCT06339658View on ClinicalTrials.gov

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

RecruitingOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Breast CancerAxillary Metastases
Interventions
PROCEDURE

Targeted axillary dissection (TAD) by ICG

Use of ICG during the targeted axillary dissection (TAD)

PROCEDURE

Targeted axillary dissection (TAD) by Blue patent

Use of Blue patent during the targeted axillary dissection (TAD)

Trial Locations (1)

08907

RECRUITING

Hospital de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
lead

Hospital Universitari de Bellvitge

OTHER